. 2009 Jan 1;48(Suppl 1):S14–S19. doi: 10.1086/591852
© 2008 by the Infectious Diseases Society of America
This article is made available via the PMC Open Access Subset for unrestricted re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the COVID-19 pandemic or until permissions are revoked in writing. Upon expiration of these permissions, PMC is granted a perpetual license to make this article available via PMC and Europe PMC, consistent with existing copyright protections.
Table 4.
Benefits and limitations of diagnostic testing versus empirical antiviral therapy.